Data completeness
2/8 — Basic
PLEGINE (phendimetrazine tartrate) by Thayer Medical is clinical pharmacology phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity.
Drug data last refreshed 6h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLEGINE (phendimetrazine tartrate) is an oral sympathomimetic amine anorectic indicated for the management of exogenous obesity. It works through central nervous system stimulation and appetite suppression, though the exact mechanism of weight loss remains incompletely understood. The drug is absorbed rapidly with an elimination half-life of approximately 3.7 hours, with renal excretion as the primary elimination route.
Pre-Launch
Pre-launch status indicates early-stage commercial team building; limited scale until market entry, but opportunity to establish brand positioning in the crowded anorectic market.
Mechanism of Action
CLINICAL PHARMACOLOGY Phendimetrazine tartrate is a sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance…
Worked on PLEGINE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.